Details for Patent: 12,458,626
Which drugs does patent 12,458,626 protect, and when does it expire?
Patent 12,458,626 protects SOHONOS and is included in one NDA.
This patent has twenty-eight patent family members in eighteen countries.
Summary for Patent: 12,458,626
| Title: | Methods for treating heterotopic ossification |
| Abstract: | The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva. |
| Inventor(s): | Clarissa Desjardins, Donna Roy GROGAN, Jeffrey Neal PACKMAN, Mark Harnett |
| Assignee: | Clementia Pharmaceuticals Inc |
| Application Number: | US18/182,463 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,458,626
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-001 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-002 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-003 | Aug 16, 2023 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-004 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,458,626
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017276835 | ⤷ Start Trial | |||
| Australia | 2022202148 | ⤷ Start Trial | |||
| Brazil | 112018075422 | ⤷ Start Trial | |||
| Canada | 3025854 | ⤷ Start Trial | |||
| Chile | 2018003502 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
